Premium
In vitro evaluation of a novel topical cream for vitiligo and psoriasis that selectively delivers NB ‐ UVB therapy when exposed to sunlight
Author(s) -
McCoy John,
Goren Andy,
Lotti Torello
Publication year - 2013
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12079
Subject(s) - vitiligo , medicine , psoriasis , dermatology , sunlight , erythema , psoralen , ultraviolet therapy , dna , physics , astronomy , biology , genetics
Ultraviolet‐ B ( UVB ) phototherapy is a well‐established mode of treatment for several types of dermatological disease. For psoriasis and vitiligo, narrow band UVB ( NB‐UVB ) phototherapy is an effective therapy, demonstrating greater efficacy and safety compared to broadband UVB or psoralen plus UVA treatments. While the treatment efficacy of NB‐UVB artificial light sources is well documented, the long term time and cost commitment of the therapy remains a barrier to treatment adherence. Natural sunlight is an ideal source of accessible UVB radiation; however, exposure to natural sunlight generally results in erythema prior to the accumulation of sufficient dosage of therapeutic wavelengths of UVB . This communication describes a novel topical cream designed to selectively deliver NB‐UVB therapy when exposed to sunlight. The topical cream when combined with natural sunlight could offer patients a more convenient phototherapy option for psoriasis and vitiligo, potentially increasing patient compliance.